Global brokerage Bernstein has commenced its coverage of the Indian healthcare sector with a positive outlook, emphasizing that innovation in niche therapies and complex specialty areas will fuel revenue growth and sustainable earnings for Indian biopharma companies. The firm provided ratings for six major stocks, with Zydus Lifesciences identified as its top 'Outperform' pick, alongside Sun Pharma and Lupin.
Conversely, Bernstein designated Biocon Ltd and Mankind Ltd with 'Underperform' ratings, citing them as non-consensus ideas. Aurobindo Pharma received a 'Market-Perform' rating. The brokerage noted the attractive valuations within Indian pharma, suggesting that policy uncertainties are diminishing.
Growth Drivers for Indian Biopharma
Bernstein's analysis indicates that Indian biopharma multiples have surpassed their ten-year average. However, the 'Outperform' rated stocks are trading below their respective ten-year averages. The market, according to Bernstein, is currently factoring in domestic market growth and pricing pressures for generic drugs in the US, but not fully appreciating the potential from 'rainmakers' – innovative products – and growth in emerging markets.
The report highlights a significant transformation in the quality of Indian biopharma, positioning the country to become a global leader in exporting innovative medicines. Proprietary models suggest that India will develop the largest network of future-ready plants globally over the next decade.
AI and Innovation: Key to Profitability
Artificial intelligence (AI) adoption is expected to be a pivotal factor, driving innovation efficiency and contributing significantly to profit margins. Bernstein estimates that enterprise-wide AI implementation could add three to four percentage points to profit margins over the next decade, with R&D and operations accounting for 70% of this AI-led profitability boost. Zydus and Lupin are identified as key beneficiaries of this trend.
Incremental innovation across six niche areas is anticipated to produce these 'rainmakers' for the Indian biopharma sector. These areas include 505(B)(2) New Drug Applications, Orphan indications, Drug-device combinations, drug repurposing in niche therapies, Metabolic peptides, and advanced RNA and cellular therapies like CAR-T. Bernstein projects these innovations to add an estimated $70-75 billion to the industry's size, potentially quadrupling the total industry to $195 billion over the next decade. Again, Zydus and Lupin are singled out as major beneficiaries.
Three Major Waves Shaping the Future
Looking ahead, Bernstein identifies three dominant waves that will shape the pharmaceutical sector:
- AI-led Innovation: Driving new discoveries and efficiencies.
- Global Access to Next-Generation Medicines: Including obesity control, mental wellbeing, nutraceuticals, preventive medicine, personal hygiene, and digital healthcare.
- Emerging Market Penetration: Increasing health infrastructure, rising disposable incomes due to AI leverage, and lifestyle shifts will drive adoption, potentially adding 100 million patients annually and creating a $400 billion opportunity from incremental innovations globally.
Bernstein concludes with a strong positive view on the sector's long-term prospects, driven by strategic innovation and market expansion.